Closed System Transfer Devices

Global Closed System Transfer Devices Market to Reach US$5.8 Billion by 2030

The global market for Closed System Transfer Devices estimated at US$1.6 Billion in the year 2023, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 19.7% over the analysis period 2023-2030. Membrane-to-Membrane Systems, one of the segments analyzed in the report, is expected to record a 20.5% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Needleless Systems segment is estimated at 17.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$415.4 Million While China is Forecast to Grow at 25.1% CAGR

The Closed System Transfer Devices market in the U.S. is estimated at US$415.4 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 25.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.6% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.9% CAGR.

Global Closed System Transfer Devices (CSTDs) Market - Key Trends & Drivers Summarized

Why Are Closed System Transfer Devices Becoming Crucial in Healthcare?

Closed System Transfer Devices (CSTDs) have become essential in healthcare environments, especially in facilities that handle hazardous drugs such as chemotherapy agents, antivirals, and other cytotoxic medications. CSTDs are engineered to prevent the escape of harmful vapors and limit exposure to healthcare professionals, protecting both patients and staff from contamination risks. They achieve this by creating an airtight seal between syringes, vials, and IV systems, ensuring that drugs are transferred in a completely closed system. This technology is particularly vital in oncology settings, where frequent handling of hazardous drugs increases the risk of exposure. CSTDs have gained prominence due to the increasing awareness of occupational hazards associated with drug handling, prompting regulatory bodies such as the Occupational Safety and Health Administration (OSHA) and the National Institute for Occupational Safety and Health (NIOSH) to recommend or mandate their use. As hospitals and pharmacies prioritize workplace safety, CSTDs are becoming indispensable tools in minimizing drug exposure risks, maintaining air quality, and ensuring safe medication practices, ultimately contributing to a safer healthcare environment.

How Are Technological Advancements Shaping the Development of CSTDs?

Technological advancements are playing a pivotal role in the evolution of Closed System Transfer Devices, enhancing their safety, usability, and compatibility with various drug delivery systems. Modern CSTDs now incorporate multi-layer filtration systems that prevent drug vapors from escaping while allowing pressure equalization, which helps minimize drug aerosolization and reduces the risk of contamination. Advanced materials, such as elastomeric and silicone-based seals, have improved device durability and compatibility with a wide range of hazardous drugs, including biologics and targeted therapies that require unique handling conditions. Additionally, some CSTDs are now designed with automated locking mechanisms and ergonomic features that allow seamless attachment and detachment, reducing the risk of accidental spillage or exposure. Smart CSTDs that can be integrated with digital health systems are also emerging, enabling real-time monitoring and tracking of drug handling activities. These advancements not only improve the safety and efficacy of CSTDs but also enhance the ease of use and compatibility with existing workflows, supporting safe drug transfer across various healthcare settings.

Which Healthcare Settings Are Driving the Demand for CSTDs Beyond Oncology?

While CSTDs are primarily used in oncology to handle chemotherapy drugs, their applications are expanding across other healthcare settings where hazardous drug handling is routine. In addition to oncology departments, CSTDs are now widely adopted in hospital pharmacies and compounding facilities, where hazardous drugs are prepared and dispensed. CSTDs help these facilities maintain compliance with safety regulations and ensure that pharmacists and technicians are protected from exposure. Hematology departments, where cytotoxic drugs are commonly used for blood disorders, are also increasingly adopting CSTDs. Long-term care facilities and home healthcare providers, where patients may require ongoing administration of hazardous medications, are seeing a growing demand for CSTDs to protect both caregivers and patients. Furthermore, CSTDs are gaining traction in veterinary medicine, where similar hazardous drug handling risks exist when treating animals with cytotoxic medications. This expanded application of CSTDs underscores their versatility and the growing recognition of occupational safety standards across diverse healthcare environments that handle potentially dangerous medications.

What’s Driving Growth in the Closed System Transfer Devices Market?

The growth in the Closed System Transfer Devices market is driven by several factors, including stringent regulatory standards, increasing awareness of occupational hazards, and advancements in drug formulations. Regulatory bodies, including OSHA and NIOSH, have emphasized the importance of protecting healthcare workers from hazardous drug exposure, leading to guidelines that promote or require the use of CSTDs in drug handling. This regulatory environment has created strong demand among healthcare facilities striving for compliance and improved safety protocols. Growing awareness of occupational health risks, particularly among healthcare professionals who routinely handle hazardous drugs, has heightened the adoption of CSTDs as a preventive measure to minimize exposure. Advancements in drug formulations, such as the rise of biologics and personalized therapies, have further driven demand for CSTDs that can safely handle complex and sensitive drugs. Additionally, the increase in cancer prevalence has led to a rise in oncology treatments and hazardous drug usage, fueling market demand. Together, these factors highlight a robust growth trajectory for the CSTDs market, as healthcare facilities increasingly adopt safer practices to protect staff, patients, and the overall work environment from hazardous exposure.

Select Competitors (Total 42 Featured) -

• B. Braun Melsungen
• Baxter International Inc.
• Becton, Dickinson and Company (BD)
• Caragen Ltd.
• Cardinal Health
• Carmel Pharma, Inc
• Codan Medizinische Geräte GmbH & Co Kg
• Corvida Medical
• Equashield LLC.
• Hospira (acquired by Pfizer)
• ICU Medical, Inc.
• JMS Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Victus, Inc.
• Yukon Medical

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.